Přejít na obsah
JNJJNJ
Zpět na vyhledávání
JNJ
JNJNYSE

Johnson & Johnson

HealthcareUnited States
273,14 US$
+1,44 US$ (+0,53 %)

Tažením v grafu vyberte úsek a zobrazí se procentuální změna.

Kapitálová struktura

Tržní kapitalizace
658,24 mld. US$
Enterprise Value
686,52 mld. US$
Hotovost
20,76 mld. US$
Celkový dluh
49,04 mld. US$
Čistý dluh
28,28 mld. US$

Valuace (TTM)

P/E
31,65×
P/E (fwd)
22,19×
P/FCF
29,61×
EV/EBITDA
19,69×
P/S
P/B
7,74×
Beta
0.23

Marže (TTM)

Hrubá marže
68,14 %
EBITDA marže
35,61 %
Provozní marže
29,19 %
Čistá marže
21,48 %
FCF marže
22,70 %

Dividenda

Dividendový výnos
1,96 %
Roční dividenda
5,36 US$
Výplatní poměr
60,79 %
Datum ex-dividendy
2026-08-25

52týdenní rozpětí

173,33 US$276,47 US$
Aktuální: 273,14 US$

O společnosti

Web

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Vedení společnosti

Mr. Joaquin Duato
Generální ředitel (CEO)
  • Mr. Joseph James Wolk CPAExecutive VP & CFO
  • Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine and R&D
  • Mr. Timothy SchmidExecutive VP & Worldwide Chairman of MedTech
  • Mr. Robert J. Decker Jr.Controller & Chief Accounting Officer
  • Mr. James SwansonExecutive VP & Chief Information Officer
  • Mr. Ryan KoorsVice President of Investor Relations
  • Mr. Dirk BrinckmanChief Compliance Officer
  • Ms. Elizabeth Forminard J.D.Executive VP & Chief Legal Officer
  • Ms. Kristen Blair MulhollandExecutive VP & Chief HR Officer